Latest Conference Articles

September 10th 2021, 5:41pm

International Myeloma Society Annual Meeting

Talquetamab, an off-the-shelf T-cell redirecting, GP3C5D-targeting agent, has continued to show promising clinical activity in patients with relapsed/refractory multiple myeloma, especially when given at the recommended phase 2 dose of 405 µg/kg weekly in subcutaneous formulation.

September 10th 2021, 5:03pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Treating patients with accelerated phase myeloproliferative neoplasm is an ongoing therapeutic challenge, due to the lack of standard treatment approaches, according to an expert.

September 10th 2021, 2:41pm

International Myeloma Society Annual Meeting

Vaishali Sanchorawala, MD, discusses the impact of renal and cardiac response on survival in patients with light chain amyloidosis. 

September 10th 2021, 12:04pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Srdan Verstovsek, MD, PhD, discusses ongoing research in myelofibrosis-related anemia.

September 9th 2021, 9:45pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Historical prognostic markers for chemoimmunotherapy have largely lost their clinically relevance in the context of targeted therapies for patients with chronic lymphocytic leukemia; however, IGHV and TP53 mutational status remain important predictive markers of response, now for novel treatments.

September 9th 2021, 9:06pm

IASLC World Conference on Lung Cancer

The combination of lurbinectedin and doxorubicin produced comparable efficacy to that of standard-of-care vincristine, cyclophosphamide, and doxorubicin or topotecan in patients with relapsed small cell lung cancer, missing the primary end point of the phase 3 ATLANTIS trial.

September 9th 2021, 9:00pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Sitting at the forefront of clinical development, pirtobrutinib and lisocabtagene maraleucel have generated significant enthusiasm in chronic lymphocytic leukemia.

September 9th 2021, 8:56pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Patients with chronic lymphocytic leukemia are at an increased risk for infection whether they are in the premalignant state of monoclonal B lymphocytosis, during active surveillance for those are treatment naïve, or are on active treatment.

September 9th 2021, 8:24pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Estimated 4-year mortality rates were greater than 10% in patients with polycythemia vera and vascular complications led to approximately one-third of these deaths, according to a retrospective analysis of the prospective REVEAL trial (NCT02252159) presented during the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting.

September 9th 2021, 8:24pm

IASLC World Conference on Lung Cancer

Adjuvant atezolizumab improved disease-free survival over best supportive care in patients with PD-L1–positive, stage II to IIIA non–small cell lung cancer, with benefit observed across most subgroups analyzed, according to data from an exploratory analysis of the phase 3 IMpower010 trial.

September 9th 2021, 7:46pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Pirtobrutinib, showcased promising efficacy signals across dose levels in previously treated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

September 9th 2021, 7:38pm

International Myeloma Society Annual Meeting

The effectiveness of this treatment in patients with multiple myeloma may be an option for a patient population who represent an unmet need.

September 9th 2021, 7:27pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Various phase 2 and 3 studies are currently underway utilizing both new and existing treatments in an effort to improve outcomes for patients with myelofibrosis.

September 9th 2021, 7:07pm

IASLC World Conference on Lung Cancer

The first-line combination of durvalumab and chemotherapy, with or without tremelimumab, led to a statistically significant improvement in progression-free survival compared with chemotherapy alone in patients with metastatic non–small cell lung cancer, according to data from the phase 3 POSEIDON trial.

September 9th 2021, 7:03pm

International Myeloma Society Annual Meeting

The safety and efficacy of the quadruplet regimen of fixed-dose isatuximab-irfcc in combination with bortezomib, lenalidomide, and dexamethasone were confirmed for patients with newly diagnosed multiple myeloma with no immediate intent for transplant.

September 9th 2021, 6:24pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Future treatment approaches for patients with polycythemia vera (PV) should center around adapting therapy using the available criteria, and eventually finding new targets.

September 9th 2021, 6:06pm

International Myeloma Society Annual Meeting

For patients with myeloma have undergone an autologous stem cell transplant and are currently on maintenance therapy with lenalidomide, minimal residual disease may be a powerful predictor of outcomes.

September 9th 2021, 5:59pm

International Myeloma Society Annual Meeting

Older patients with newly diagnosed multiple myeloma who are ineligible for chemotherapy or transplant may derive a greater benefit when treated with daratumumab plus lenalidomide and dexamethasone compared with lenalidomide and dexamethasone.

September 9th 2021, 5:24pm

Society of Hematologic Oncology Annual Meeting (SOHO)

The addition of venetoclax to fludarabine, cytarabine, idarubicin and G-CSF resulted in high complete response rates and enables a high consolidative allogeneic transplantation rate in patients with newly diagnosed acute myeloid leukemia.

September 9th 2021, 5:15pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Catherine Callaghan Coombs, MD, discusses the efficacy results of the ongoing phase 1/2 BRUIN study with pirtobrutinib in chronic lymphocytic leukemia.